Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

Erman, Mustafa; Biswas, Bivas; Danchaivijitr, Pongwut; Chen, Lingwu; Wong, Yoke Fui; Hashem, Tarek; Lim, Chun Sen; Karabulut, Bülent; Chung, Hsiao-Jen; Chikatapu, Chandrasekhar; Ingles, Sara; Slimane, K.; Kanesvaran, Ravindran

doi:10.1186/s12885-021-08848-8

Cited by 2 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data are like that reported in a previous long-term response study of sunitinib and pazopanib with accordance to the general characteristics of mRCC patients [ 22 – 24 ].…”

Section: Discussionsupporting

confidence: 92%

“…Age < 65 years, previous nephrectomy, absence of bone or lung metastases and favorable MSKCC risk status were the factors associated with long-term responses in mRCC patients receiving TKI as first line therapy [ 22 – 24 ]. Accordingly with previous studies, NLR is significantly associated with poorer OS and PFS, and lower rates of response and clinical benefit, after ICI therapy across multiple cancer types [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Messina,

Catalano,

Roviello

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

Background Although nivolumab prolongs overall survival (OS) in pretreated patients with metastatic renal cell carcinoma (mRCC), underlining clinical and biological features of long-term responses are still to be determined. This study aims to investigate clinical and pathological characteristics of mRCC patients who achieved long-term responses during nivolumab treatment. Materials and methods A retrospective analysis was performed on mRCC patients receiving nivolumab as second or further therapy line between May 2016 and January 2019 in 34 Italian Oncology Centres. Outcome assessments and logistic regression were performed to evaluate factors influencing long-term responses. Results A total of 571 patients with a median age of 61 years (range 17–85) were included in the analysis. With a median follow-up of 22.1 (1.0–89.0) months, 23.1% of patients were 2-year progression-free on treatment with nivolumab, hence they were categorized as long-term responders. Baseline characteristics, including age, gender, and histology, were similar between long- and short-term responders. Karnofsky Performance Status ≥ 80% was significantly associated with long-term response (p = 0.02), while bone metastases (p = 0.03), International mRCC Database Consortium intermediate-poor risk (p < 0.01) and Neutrophil-to-Lymphocyte Ratio ≥ 3.2 (p = 0.02) were associate with short-term responses. Long-term responders exhibited a median progression-free survival of 55.0 months versus 4.0 months of the short-term responders. The median OS was not reached in long-term responders while it was 17.0 months for short*term responders. Conclusion This retrospective analysis sheds light on factors associated with long-term response to nivolumab in mRCC. Understanding these clinical features will be essential for selecting patients who may mostly benefit from immunotherapy.

show abstract

“…Our data are like that reported in a previous long-term response study of sunitinib and pazopanib with accordance to the general characteristics of mRCC patients [ 22 – 24 ].…”

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Messina,

Catalano,

Roviello

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Our data are like that reported in a previous long-term response study of sunitinib and pazopanib with accordance to the general characteristics of mRCC patients [24][25][26].…”

Section: Discussionsupporting

confidence: 92%

“…Age < 65 years, previous nephrectomy, absence of bone or lung metastases and favorable MSKCC risk status were the factors associated with long-term responses in mRCC patients receiving TKI as rst line therapy [24][25][26]. Accordingly with previous studies, NLR is signi cantly associated with poorer OS and PFS, and lower rates of response and clinical bene t, after ICI therapy across multiple cancer types [27].…”

Section: Discussionmentioning

confidence: 80%

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study

Messina,

Catalano,

roviello

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Although nivolumab prolongs overall survival (OS) in pretreated patients with metastatic renal cell carcinoma (mRCC), underlining clinical and biological features of long-term responses are still to be determined. This study aims to investigate clinical and pathological characteristics of mRCC patients who achieved long-term responses during nivolumab treatment. Materials and Methods: A retrospective analysis was performed on mRCC patients receiving nivolumab as second or further therapy line between May 2016 and January 2019 in 34 Italian Oncology Centres. Outcome assessments and logistic regression were performed to evaluate factors influencing long-term responses. Results: A total of 571 patients with a median age of 61 years (range 17-85) were included in the analysis. With a median follow-up of 22.1 (1.0-89.0) months, 23.1% of patients were 2-year progression-free on treatment with nivolumab, hence they were categorized as long-term responders. Baseline characteristics, including age, gender, and histology, were similar between long and short-term responders. Karnofsky Performance Status ≥80% was significantly associated with long-term response (p=0.02), while bone metastases (p=0.03), International mRCC Database Consortium intermediate-poor risk (p<0.01) and Neutrophil-to-Lymphocyte Ratio ≥3.2 (p=0.02) were associate with short-term responses. Long-term responders exhibited a median progression free survival of 55.0 months versus 4.0 months of the short-term responders. The median OS was not reached in long-term responders while it was 17.0 months for short term responders. Conclusion: This retrospective analysis sheds light on factors associated with long-term response to nivolumab in mRCC. Understanding these clinical features will be essential for selecting patients who may mostly benefit from immunotherapy.

show abstract

Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

Cited by 2 publications

References 1 publication

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study

Contact Info

Product

Resources

About